These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29165076)

  • 21. Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.
    van Witteloostuijn SB; Pedersen SL; Jensen KJ
    ChemMedChem; 2016 Nov; 11(22):2474-2495. PubMed ID: 27775236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4.
    Griffiths K; Binder U; McDowell W; Tommasi R; Frigerio M; Darby WG; Hosking CG; Renaud L; Machacek M; Lloyd P; Skerra A; Foley M
    MAbs; 2019 Oct; 11(7):1331-1340. PubMed ID: 31156041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
    Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
    J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-Deficient Lep(ob/ob) Mice.
    Bolze F; Morath V; Bast A; Rink N; Schlapschy M; Mocek S; Skerra A; Klingenspor M
    Endocrinology; 2016 Jan; 157(1):233-44. PubMed ID: 26492472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.
    Schlapschy M; Theobald I; Mack H; Schottelius M; Wester HJ; Skerra A
    Protein Eng Des Sel; 2007 Jun; 20(6):273-84. PubMed ID: 17595342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surface protein engineering increases the circulation time of a cell membrane-based nanotherapeutic.
    Krishnamurthy S; Muthukumaran P; Jayakumar MKG; Lisse D; Masurkar ND; Xu C; Chan JM; Drum CL
    Nanomedicine; 2019 Jun; 18():169-178. PubMed ID: 30853651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.
    Podust VN; Balan S; Sim BC; Coyle MP; Ernst U; Peters RT; Schellenberger V
    J Control Release; 2016 Oct; 240():52-66. PubMed ID: 26497931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins.
    Brandl F; Merten H; Zimmermann M; Béhé M; Zangemeister-Wittke U; Plückthun A
    J Control Release; 2019 Aug; 307():379-392. PubMed ID: 31252038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Affinity Purification of Long-Acting PASylated Proteins with Therapeutic Potential Using L-Prolinamide for Mild Elution.
    Schilz J; Clement C; Greiner F; Skerra A
    Angew Chem Int Ed Engl; 2022 Jun; 61(25):e202200079. PubMed ID: 35325504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.
    Zeb A; Rana I; Choi HI; Lee CH; Baek SW; Lim CW; Khan N; Arif ST; Sahar NU; Alvi AM; Shah FA; Din FU; Bae ON; Park JS; Kim JK
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33291312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new CZE method for profiling human serum albumin and its related forms to assess the quality of biopharmaceuticals.
    Alahmad Y; Tran NT; Le Potier I; Forest E; Jorieux S; Taverna M
    Electrophoresis; 2011 Jan; 32(2):292-9. PubMed ID: 21254128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
    Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
    Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life.
    Najjari A; Shahbazmohammadi H; Nojoumi SA; Omidinia E
    ACS Omega; 2022 Dec; 7(50):46118-46130. PubMed ID: 36570261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.
    Strohl WR
    BioDrugs; 2015 Aug; 29(4):215-39. PubMed ID: 26177629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the future of PEGylated therapies?
    Swierczewska M; Lee KC; Lee S
    Expert Opin Emerg Drugs; 2015; 20(4):531-6. PubMed ID: 26583759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physicochemical characterization of biopharmaceuticals.
    Parr MK; Montacir O; Montacir H
    J Pharm Biomed Anal; 2016 Oct; 130():366-389. PubMed ID: 27324698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-generation biopharmaceuticals.
    Walsh G
    Eur J Pharm Biopharm; 2004 Sep; 58(2):185-96. PubMed ID: 15296948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
    Turecek PL; Bossard MJ; Schoetens F; Ivens IA
    J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.